KRAS and neoplasm: KP was associated with the increased expression of PD-L1 and mutational burden, showing a remarkable clinical benefit for PD-1 inhibitors (30), while KL was significantly associated with PD-L1 negative in tumor mutational burden intermediate-high and represents a major driver of primary resistance to PD-1 blockade in KRAS mutant (8).